Treatment and management of myelofibrosis in the era of JAK inhibitors

about

Treatment of Myelofibrosis: Old and New Strategies.Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics.

P2860

Q39349869-CB1C0833-6EAB-486E-A50D-871E12AFAD3F Q54981699-34598997-3300-4470-96D9-5F093BE776C2

P2860

Treatment and management of myelofibrosis in the era of JAK inhibitors

Item

http://www.wikidata.org/entity/Q38132739

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Treatment and management of myelofibrosis in the era of JAK inhibitors

@en

type

Item

label

Treatment and management of myelofibrosis in the era of JAK inhibitors

@en

prefLabel

Treatment and management of myelofibrosis in the era of JAK inhibitors

@en

P1476

Treatment and management of myelofibrosis in the era of JAK inhibitors

@en

P2093

Claire N Harrison

http://www.w3.org/2001/XMLSchema#string

Clodagh Keohane

http://www.w3.org/2001/XMLSchema#string

Deepti H Radia

http://www.w3.org/2001/XMLSchema#string

P2860

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

Histone deacetylase inhibitors: Potential in cancer therapy

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

Anticancer activities of histone deacetylase inhibitors

A gain-of-function mutation of JAK2 in myeloproliferative disorders

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

Pomalidomide is active in the treatment of anemia associated with myelofibrosis

A phase-2 trial of low-dose pomalidomide in myelofibrosis.

P304

189-198

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/BTT.S34942

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256291411

http://www.w3.org/2001/XMLSchema#string

P698

23990704

http://www.w3.org/2001/XMLSchema#string

P932

3753053

http://www.w3.org/2001/XMLSchema#string

Treatment and management of myelofibrosis in the era of JAK inhibitors

about

P2860

P2860

Treatment and management of myelofibrosis in the era of JAK inhibitors

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932